See What HealthDay Can Do For You
Contact Us

Ovary-Fallopian Surgery Linked to Lower Cancer Risk

Women opting for salpingo-oophorectomy see lower risk of some gynecological, breast cancers

TUESDAY, Feb. 12 (HealthDay News) -- In a study separately evaluating the effect of risk-reducing salpingo-oophorectomy (RRSO) on breast and gynecological cancer risk in BRCA1 and BRCA2 mutation carriers, the procedure was associated with lower BRCA1-associated gynecologic cancer risk and BRCA2-associated breast cancer risk, according to research published online Feb. 11 in the Journal of Clinical Oncology.

Noah D. Kauff, M.D., of Memorial Sloan-Kettering Cancer Center in New York City, and colleagues analyzed data from a prospective study in which 1,079 women, aged 30 and older, with a BRCA1 or BRCA2 mutation chose RRSO or observation.

RRSO was related to an 85 percent reduction in BRCA1-associated gynecological cancer risk and a 72 percent lower BRCA2-associated breast cancer risk. The results showed a trend toward protection against BRCA1-associated breast cancer and BRCA2-associated gynecological cancer (invasive epithelial carcinoma of the ovary, fallopian tube or peritoneum), but failed to reach significance.

"The present report provides strong confirmation that RRSO remains the most effective risk-reduction strategy for the prevention of BRCA1-associated gynecologic cancer," the authors write. "Until more effective ovarian cancer surveillance is available, RRSO should be discussed with all carriers of BRCA mutations who have completed childbearing and have entered the risk period for gynecologic cancers."

Abstract
Full Text (subscription or payment may be required)

Physician's Briefing

HealthDay

HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.